Aehr Test Systems
AEHR
$96.93
+3.68%
Aehr Test Systems designs, manufactures, and markets advanced test and burn-in equipment for the semiconductor industry, with its ABTS and FOX-P families of systems used to stress-test logic, optical, and memory integrated circuits, particularly for automotive, mobility, and increasingly AI/data-center applications. As a small-cap niche player with only 138 employees, Aehr occupies a specialized position in the semiconductor capital equipment supply chain, selling high-value, low-volume systems (its FOX-XP and WaferPak contactors) rather than competing with broad-line test giants like Advantest or Teradyne. The current investor narrative has been transformed by the company's strategic pivot away from a concentrated EV/automotive customer base toward AI processor and power-semiconductor testing, a shift that management says drove record bookings and prompted headlines about revenue potentially tripling next year. This AI-infrastructure angle, combined with a return to profitability in the most recent quarter, has made AEHR one of the more volatile and heavily debated small-cap semiconductor names, with bulls pointing to a massive addressable market expansion and bears questioning customer concentration, lumpy order patterns, and a valuation that already discounts heroic execution.…
AEHR
Aehr Test Systems
$96.93
Related headlines
Investment Opinion: Should I buy AEHR Today?
The synthesized recommendation is Hold with a bullish bias, reflecting a genuine fundamental inflection offset by an extreme valuation that already discounts heroic execution. The analyst consensus is a strong buy with a $128.00 average target, implying +36.9% upside, but the stock's 56.6x sales multiple and 67.6x forward PE leave no margin for error, making the risk/reward balanced rather than compelling at current levels.
The supporting evidence for a constructive view includes: (1) Q4 revenue growth of 40.2% year-over-year and 92% sequentially, validating the AI pivot; (2) gross margin recovery to 40.6% from 32.7% in the prior quarter; (3) a return to profitability with $1.39 million in net income; (4) a fortress balance sheet with $116.5 million in cash and debt-to-equity of 0.045; and (5) unanimous strong buy analyst ratings with a $128 average target. However, these positives are tempered by negative TTM free cash flow of -$5.38 million, a 345-day cash conversion cycle, and a valuation that is 5-10x the sector's sales multiple.
The biggest risks that could invalidate the thesis are: (1) customer concentration and lumpy orders, which could cause revenue to miss the $288.1 million estimate; (2) continued negative free cash flow requiring dilutive financing; and (3) multiple compression if growth decelerates. The rating would upgrade to Buy if the stock pulls back to the $76-$80 support zone (implying ~15-20% downside) or if the company demonstrates sustained positive free cash flow and diversified customer wins. It would downgrade to Sell if revenue growth decelerates below 20% year-over-year or if a major customer cancels orders. Relative to its own history, the 56.6x PS ratio is in the upper-middle of its 11x-143x range, suggesting the stock is fairly valued to slightly overvalued, while relative to peers it is significantly overvalued.
Sign up to view all
AEHR 12-Month Price Forecast
Aehr presents a classic high-risk, high-reward small-cap semiconductor story: the AI-driven revenue inflection is real, with Q4 revenue up 40.2% year-over-year and a return to profitability, but the valuation at 56.6x sales already prices in near-flawless execution of the $288.1 million consensus revenue estimate. The unanimous strong buy analyst consensus and $128 average target suggest the sell-side sees the recent 13.4% pullback as a buying opportunity, but the stock's 3.07 beta and -47.62% max drawdown mean investors must tolerate extreme volatility. The key tension is whether the AI order flow is durable and scalable; if the company reports another quarter of strong bookings and positive free cash flow, the stock could re-rate toward $147-$175, but any sign of order lumpiness or customer concentration could trigger a sharp correction toward $76-$110. I would upgrade to bullish if the stock pulls back to the $76-$80 support zone with intact fundamentals, and downgrade to bearish if revenue growth decelerates below 20% or free cash flow remains negative for another two quarters.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Aehr Test Systems's 12-month outlook, with a consensus price target around $128.00 and implied upside of +32.0% versus the current price.
Average Target
$128.00
0 analysts
Implied Upside
+32.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$110 - $175
Analyst target range
Five analysts cover AEHR, and the consensus recommendation is a strong buy with a recommendation mean of 1.0 (where 1.0 is a strong buy on a 1-5 scale), reflecting unanimous bullishness among the covering firms. The average price target is $128.00, which implies approximately +36.9% upside from the current price of $93.49, and the consensus is clearly bullish, with the average target well above the current trading level. This bullish stance is notable given the stock's recent 13.4% one-month decline, suggesting analysts view the pullback as a buying opportunity rather than a deterioration in the thesis, and the estimated EPS average of $1.65 and revenue average of $288.1 million underpin the optimistic outlook. The target range spans from a low of $110.00 to a high of $175.00, a spread of $65 or roughly 59% of the low target, which signals meaningful disagreement about the magnitude of the AI-driven ramp. The high target of $175.00 implies roughly +87% upside and likely assumes the company captures multiple large AI test orders, achieves the $288 million revenue estimate, and expands margins toward historical 50%+ gross margin levels, while the low target of $110.00 still implies +17.7% upside and likely prices in solid but less explosive growth with some margin pressure from competition or customer concentration. The institutional ratings history shows a constructive shift: William Blair upgraded to Outperform from Market Perform on 2026-03-02, and Craig-Hallum has held at Hold since January 2026 after downgrading from Buy in March 2024, indicating that sell-side sentiment has improved alongside the AI pivot, though the presence of Hold ratings from Freedom Broker and Craig-Hallum suggests some analysts remain cautious on valuation and execution risk. The relatively tight clustering of targets above the current price, combined with the strong buy consensus, indicates that the analyst community sees the recent pullback as a temporary dislocation, but the wide absolute range and the stock's 3.07 beta mean investors should expect continued high volatility around any target price.
Drowning in data?
Find the real signal!
Bulls vs Bears: AEHR Investment Factors
The bull case rests on a genuine fundamental inflection: revenue grew 40.2% year-over-year in Q4, gross margins recovered to 40.6%, and the company returned to profitability with $1.39 million in net income, all while maintaining a pristine balance sheet with $116.5 million in cash and virtually no debt. The AI pivot has driven record bookings of $37.2 million and unanimous strong buy analyst ratings with a $128 average target, implying 36.9% upside. However, the bear case is equally compelling: the stock trades at 56.6x sales, roughly 5-10x peer multiples, leaving no room for error, while negative free cash flow, severe customer concentration, and a 3.07 beta create substantial downside risk. The recent 13.4% one-month decline and -20.9 point three-month relative underperformance suggest the market is already questioning the sustainability of the ramp. The single most important tension is whether the AI-driven order flow is durable and scalable enough to justify the $288.1 million revenue estimate; if it is, the stock is undervalued, but if orders prove lumpy or concentrated, the valuation could compress violently. On balance, the bull evidence currently has a slight edge given the tangible revenue and margin inflection, but the margin of safety is thin.
Bullish
- Revenue re-acceleration validates AI pivot: Q4 FY2026 revenue of $19.75 million grew 40.2% year-over-year and 92% sequentially from Q3's $10.31 million, marking a sharp inflection after four quarters of roughly $10-14 million. The $37.2 million in new bookings reported alongside the print suggests the AI-driven order ramp is translating into real top-line momentum.
- Profitability inflection with margin recovery: Q4 net income swung to $1.39 million (7.0% net margin) from losses of $3.20 million, $3.23 million, and $2.08 million in the prior three quarters. Gross margin expanded to 40.6% from 32.7%, 25.7%, and 33.9%, and operating income of -$993 thousand was near breakeven despite $3.65 million in R&D spending.
- Fortress balance sheet with zero debt: The company holds $116.5 million in cash after a $79.9 million equity issuance, with a current ratio of 10.33 and debt-to-equity of just 0.045. This provides ample runway to fund growth internally without financing pressure, a rarity for a small-cap semiconductor equipment maker.
- Unanimous strong buy analyst consensus: All five covering analysts rate AEHR a strong buy (recommendation mean of 1.0), with an average price target of $128.00 implying +36.9% upside from $93.49. The target range of $110-$175 is entirely above the current price, suggesting analysts view the recent 13.4% one-month decline as a buying opportunity.
Bearish
- Extreme valuation leaves no margin for error: AEHR trades at 56.6x TTM sales and 56.9x EV/Sales, roughly 5-10x the 5-10x sales multiple of mature semiconductor equipment peers. The forward PE of 67.6x is only justifiable if the company delivers the $288.1 million revenue estimate and $1.65 EPS, leaving essentially no room for execution missteps.
- Severe customer concentration and lumpy orders: The company's revenue is driven by a small number of large orders, as evidenced by the sequential revenue jump from $10.31 million to $19.75 million in a single quarter. This lumpiness makes forecasting unreliable and exposes the stock to sharp declines if a major customer delays or cancels orders.
- Negative free cash flow despite revenue surge: TTM free cash flow remains negative at -$5.38 million, and Q4 operating cash flow was only $1.21 million despite the revenue surge, reflecting a $5.69 million accounts receivable build. The 317-day days-of-inventory-outstanding and 345-day cash conversion cycle indicate a capital-intensive working capital model that will consume cash as revenue scales.
- Extreme volatility with 3.07 beta: AEHR's beta of 3.067 means it is more than three times as volatile as the broader market, with daily swings of 5-10% routine. The stock has a max drawdown of -47.62% and has already fallen 36% from its August peak of $145.61 to $93.49, demonstrating its capacity for rapid value destruction.
AEHR Technical Analysis
AEHR is in a powerful but extraordinarily volatile uptrend, with a 1-year price change of +205.8% and a year-to-date gain of +321.9%, massively outperforming the S&P 500's +15.0% 1-year and +11.7% YTD returns. At the current price of $93.49, the stock sits at roughly 58% of its 52-week range (52-week low of $18.70, high of $147.40), meaning it has surrendered a substantial portion of its peak gains despite the huge annual advance. This mid-range positioning after a parabolic run suggests the stock is in a digestion/consolidation phase rather than a clean breakout, with the memory of the $147.40 high acting as a psychological ceiling and the $18.70 low a distant but stark reminder of how far this name can fall. Momentum has clearly decelerated from the peak: the 1-month change is -13.4% and the 3-month change is -18.9%, both sharply negative and diverging from the still-strong 6-month (+170.8%) and 1-year (+205.8%) trends. This divergence signals that the explosive April-August rally (which peaked at $145.61 on August 17) has given way to a corrective phase, with the stock falling from $145.61 to $93.49 in about a month, a roughly 36% drawdown. Relative strength confirms the recent weakness: AEHR underperformed SPY by -12.4 percentage points over the past month and -20.9 points over three months, even as it outperformed by +190.8 points over a full year, indicating the market is taking profits and reassessing the near-term growth trajectory. Key technical levels are well defined: resistance sits at the 52-week high of $147.40, and a decisive breakout above that level would signal renewed institutional conviction and likely require a fresh fundamental catalyst such as a major new AI order. Support lies in the $76-$80 zone (the early-September and late-August lows around $76.27-$80.81), with the 52-week low of $18.70 as the ultimate floor; a breakdown below $76 would suggest the corrective trend is deepening and could target the $65-$70 area seen in late July. With a beta of 3.067, AEHR is more than three times as volatile as the broader market, meaning daily swings of 5-10% are routine and position sizing must be dramatically smaller than for a typical equity; the max drawdown of -47.62% underscores that this stock can lose nearly half its value in a single correction, as it effectively did from the August peak.
Beta
3.07
3.07x market volatility
Max Drawdown
-47.6%
Largest decline past year
52-Week Range
$19-$147
Price range past year
Annual Return
+223.6%
Cumulative gain past year
| Period | AEHR Return | S&P 500 |
|---|---|---|
| 1m | -4.7% | +1.0% |
| 3m | -5.3% | +5.4% |
| 6m | +148.3% | +17.8% |
| 1y | +223.6% | +16.5% |
| ytd | +337.4% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AEHR Fundamental Analysis
Aehr's revenue trajectory has inflected sharply upward after a prolonged trough, with the most recent quarter (ending 2026-05-29) delivering $19.75 million in revenue, up 40.2% year-over-year, a dramatic acceleration from the prior three quarters of $10.31 million, $9.88 million, and $10.97 million. That sequential jump of roughly 92% from Q3 to Q4 reflects the AI-driven order ramp, and the revenue mix shows systems at $6.76 million, contactors at $2.61 million, and services at $1.59 million, indicating the core FOX system business is leading the recovery. The multi-quarter trend is unmistakably one of re-acceleration: after four consecutive quarters of roughly $10-14 million in revenue with negative growth, the Q4 print and the reported $37.2 million in new bookings suggest the AI pivot is translating into real top-line momentum, though the lumpiness of a small number of large orders remains a key risk to the sustainability of this growth. Profitability has swung back into positive territory, with Q4 net income of $1.39 million (a 7.0% net margin) versus losses of $3.20 million, $3.23 million, and $2.08 million in the prior three quarters, and gross margin expanded to 40.6% from 32.7%, 25.7%, and 33.9% in the preceding periods. While the trailing net margin is still -14.3% and operating margin -28.3% on a TTM basis, the quarterly inflection is meaningful, and the 40.6% gross margin, though below the 50%+ levels Aehr enjoyed in FY2022-2023, is recovering as volumes return. The company remains marginally unprofitable on a TTM basis (EPS of -$0.0025, ROE of -3.2%, ROA of -4.5%), but the trajectory toward profitability is clear if the AI order flow persists, and the Q4 operating income of -$993 thousand was close to breakeven despite heavy R&D spending of $3.65 million. The balance sheet is exceptionally strong, with a current ratio of 10.33, debt-to-equity of just 0.045, and cash of $116.5 million at the end of Q4 after a $79.9 million common stock issuance, providing ample runway to fund growth internally without external financing pressure. However, free cash flow remains negative on a TTM basis at -$5.38 million, and Q4 operating cash flow was only $1.21 million despite the revenue surge, reflecting working capital absorption from a $5.69 million accounts receivable build and inventory dynamics; the cash flow-to-debt ratio of 0.12 and price-to-free-cash-flow ratio of 2,629x highlight that the company is not yet generating meaningful cash relative to its valuation, and the 317-day days-of-inventory-outstanding and 345-day cash conversion cycle indicate a capital-intensive working capital model that will require continued cash consumption as revenue scales.
Quarterly Revenue
$19751000.0B
2026-05
Revenue YoY Growth
+40.2%
YoY Comparison
Gross Margin
40.6%
Latest Quarter
Free Cash Flow
$-5376000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AEHR Overvalued?
Because Aehr's trailing net income is negative (TTM EPS of -$0.0025, trailing PE of -401.4x), the PE ratio is not meaningful, so the primary valuation metric is the price-to-sales ratio, which stands at an extraordinary 56.6x TTM and an EV/Sales of 56.9x. The forward PE of 67.6x, based on consensus estimated EPS of $1.65, is the more relevant profitability-based metric and implies the market expects a dramatic earnings inflection from the current near-breakeven level; the enormous gap between the negative trailing PE and the positive 67.6x forward PE captures the market's bet on explosive EPS growth as AI-driven revenue scales. On a price-to-book basis, the stock trades at 12.9x, and the PEG ratio of -5.22 is distorted by the negative trailing earnings base, so it offers little insight. Compared to the broader semiconductor industry, where mature equipment makers typically trade at 5-10x sales and 20-30x forward earnings, AEHR's 56.6x sales and 67.6x forward PE represent a massive premium, roughly 5-10x the sector's sales multiple. This premium is only justifiable if the company delivers on the consensus revenue estimate of $288.1 million (versus TTM revenue of roughly $50 million), which would represent nearly a 6x increase, and if it sustains the 40%+ gross margins and converts revenue to profit at the estimated $1.65 EPS. The premium reflects Aehr's positioning as a pure-play beneficiary of AI power-semiconductor testing with a small float and high growth optionality, but it leaves essentially no margin for error. Historically, AEHR's PS ratio has ranged from about 11x (May 2022) to 143x (May 2026), with the current 56.6x sitting in the upper-middle of that band but well below the 143x peak reached at the height of the AI enthusiasm in Q4 FY2026. The stock's historical PE has swung wildly between 3.5x and 465x depending on the earnings cycle, making the current 67.6x forward PE look reasonable only if the forward estimates are achieved; relative to its own history, the valuation is elevated but not at the extreme, suggesting the market has already priced in significant growth while retaining some upside if execution exceeds expectations.
PE
-401.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~168x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-232.2x
Enterprise Value Multiple
Investment Risk Disclosure
Aehr's financial risk profile is dominated by its negative free cash flow and working capital intensity. Despite Q4 revenue of $19.75 million, TTM free cash flow is -$5.38 million, and Q4 operating cash flow was only $1.21 million, reflecting a $5.69 million accounts receivable build. The cash conversion cycle of 345 days and days-of-inventory-outstanding of 317 days mean that as revenue scales, the company will consume significant cash to fund receivables and inventory, potentially requiring further equity dilution despite its $116.5 million cash balance. Additionally, the company remains marginally unprofitable on a TTM basis with a net margin of -14.3% and operating margin of -28.3%, and its revenue is highly concentrated in a small number of large orders, making earnings volatile and unpredictable.
Market and competitive risks are amplified by AEHR's extreme valuation and volatility. At 56.6x TTM sales and 56.9x EV/Sales, the stock trades at a massive premium to mature semiconductor equipment peers that typically command 5-10x sales, leaving it vulnerable to sharp multiple compression if growth disappoints. The beta of 3.067 means the stock is more than three times as volatile as the broader market, and its recent underperformance of -12.4 percentage points versus SPY over the past month suggests sector rotation or profit-taking is underway. Competitive threats from larger, better-capitalized test equipment makers like Advantest and Teradyne could pressure pricing and margins, while the company's niche focus on AI power-semiconductor testing exposes it to rapid technological shifts and potential customer insourcing.
The worst-case scenario for AEHR would be a combination of delayed AI orders, a major customer cancellation, and a broader semiconductor capital equipment downturn. In this scenario, revenue could fail to reach the $288.1 million consensus estimate, causing the stock to retest its 52-week low of $18.70, which represents a -80% decline from the current price of $93.49. Even a less severe bear case, such as the analyst low target of $110.00, implies upside, but the stock's historical max drawdown of -47.62% and its 36% decline from the August peak of $145.61 to $93.49 demonstrate that a 50%+ correction is entirely plausible. Investors could lose 35-50% from current levels in a moderate adverse scenario, with the $76-$80 support zone as the first major test and the $18.70 low as the ultimate floor.
FAQ
The most severe risk is customer concentration and lumpy order patterns, as evidenced by the sequential revenue jump from $10.31 million to $19.75 million in a single quarter, which makes forecasting unreliable and exposes the stock to sharp declines if a major customer delays or cancels orders. The second major risk is the extreme valuation at 56.6x TTM sales, which leaves no margin for error and could compress violently if growth disappoints. Third, the company has negative TTM free cash flow of -$5.38 million and a 345-day cash conversion cycle, meaning it will consume cash as it scales and may need dilutive financing. Finally, the stock's 3.07 beta and -47.62% max drawdown mean it is more than three times as volatile as the market, with daily swings of 5-10% routine, making it unsuitable for risk-averse investors.
Our 12-month forecast assigns a 50% probability to the base case, with a target range of $110-$128, implying +17.7% to +36.9% upside from the current $93.49. The base case assumes revenue reaches $200-250 million, slightly below the $288.1 million consensus, with gross margins stabilizing at 40-45%. The bull case (30% probability) targets $147-$175, assuming the company hits the consensus revenue estimate, expands margins toward 50%, and generates positive free cash flow. The bear case (20% probability) targets $76-$110, driven by a major order delay or cancellation and a sector downturn. The most likely scenario is the base case, with the key assumption being that Aehr delivers solid but not explosive growth, and the stock remains volatile around the $128 analyst average target.
AEHR appears significantly overvalued relative to peers and its own history on most metrics. The stock trades at 56.6x TTM sales and 56.9x EV/Sales, roughly 5-10x the 5-10x sales multiple of mature semiconductor equipment makers like Advantest and Teradyne. The forward PE of 67.6x is also well above the 20-30x range typical for the sector, and the price-to-book ratio of 12.9x is elevated. Relative to its own history, the PS ratio has ranged from 11x to 143x, so the current 56.6x is in the upper-middle of that band but well below the 143x peak. The market is pricing in the consensus revenue estimate of $288.1 million, a nearly 6x increase from TTM revenue of roughly $50 million, and EPS of $1.65. If the company delivers, the valuation could be justified, but any shortfall would likely trigger a sharp multiple compression.
From a risk/reward perspective, AEHR is a high-risk, high-reward proposition that is only suitable for aggressive investors. The stock trades at $93.49, implying +36.9% upside to the $128 analyst average target, and the unanimous strong buy consensus suggests the sell-side sees the recent 13.4% pullback as a buying opportunity. However, the valuation at 56.6x TTM sales and 67.6x forward PE leaves no margin for error, and the company's negative free cash flow of -$5.38 million and 345-day cash conversion cycle mean it will need to execute flawlessly to justify the price. The biggest downside risk is a retest of the $76-$80 support zone, which would represent a 15-20% decline, or a more severe drop to the 52-week low of $18.70 in a bear scenario. For investors with a high risk tolerance and a 3-5 year horizon, a small position could be justified, but it is not a good buy for conservative or income-oriented investors.
AEHR is best suited for long-term investors with a 3-5 year horizon who can tolerate extreme volatility, as the company is in an early growth stage with a small revenue base of roughly $50 million TTM and a massive addressable market in AI semiconductor testing. The stock pays no dividend (payout ratio of 0), so returns depend entirely on capital appreciation, and its 3.07 beta means short-term trading requires constant monitoring and tight risk management. Earnings visibility is low due to customer concentration and lumpy orders, making it a poor candidate for short-term swing trading unless one has a high conviction on a specific catalyst. A minimum holding period of 2-3 years is suggested to allow the AI pivot to fully play out, but position sizing should be small (e.g., 1-3% of a portfolio) to account for the risk of a 50%+ drawdown.
